Clozapine-induced gastroesophageal rumination in 22q11.2 Deletion Syndrome. A case report on gastroesophageal side effects management without renouncing clozapine's effectiveness
- PMID: 34084508
- PMCID: PMC8142464
- DOI: 10.1002/ccr3.4134
Clozapine-induced gastroesophageal rumination in 22q11.2 Deletion Syndrome. A case report on gastroesophageal side effects management without renouncing clozapine's effectiveness
Abstract
Despite entailing more severe and uncommon side effects in 22q11.2DS compared to idiopathic schizophrenia, we strongly believe that clozapine should continue to be considered the gold standard for all treatment-resistant schizophrenia, even in 22qDS.
Keywords: genetics; pharmacology; psychiatry.
© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Conflict of interest statement
None declared.
Similar articles
-
A case study of the utilization of clozapine treatment for treatment-resistant schizophrenia associated with 22q11.2 deletion syndrome.Neuropsychopharmacol Rep. 2023 Jun;43(2):272-276. doi: 10.1002/npr2.12333. Epub 2023 Mar 16. Neuropsychopharmacol Rep. 2023. PMID: 36929244 Free PMC article.
-
Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use.Expert Opin Drug Saf. 2016 Sep;15(9):1193-203. doi: 10.1080/14740338.2016.1191468. Epub 2016 Jun 1. Expert Opin Drug Saf. 2016. PMID: 27207070 Review.
-
Clozapine administered once versus twice daily: does it make a difference?Med Hypotheses. 2014 Feb;82(2):225-8. doi: 10.1016/j.mehy.2013.11.043. Epub 2013 Dec 9. Med Hypotheses. 2014. PMID: 24360486
-
Stimulant treatment effectiveness, safety and risk for psychosis in individuals with 22q11.2 deletion syndrome.Eur Child Adolesc Psychiatry. 2022 Sep;31(9):1367-1375. doi: 10.1007/s00787-021-01780-z. Epub 2021 Apr 19. Eur Child Adolesc Psychiatry. 2022. PMID: 33871687
-
Where to position clozapine: re-examining the evidence.Can J Psychiatry. 2010 Oct;55(10):677-84. doi: 10.1177/070674371005501007. Can J Psychiatry. 2010. PMID: 20964947 Review.
References
-
- Botto LD, May K, Fernhoff PM, et al. A population‐based study of the 22q11.2 Deletion: Phenotype, incidence, and contribution to major birth defects in the population. Pediatrics. 2003;112:101‐107. - PubMed
-
- Murphy KC. Schizophrenia and velo‐cardio‐facial syndrome. Lancet. 2002;359:426‐430. - PubMed
-
- Verhoeven WMA, Egger JIM. Atypical antipsychotics and relapsing psychoses in 22q11.2 deletion syndrome: A long‐term evaluation of 28 patients. Pharmacopsychiatry. 2015;48:104‐110. - PubMed
Publication types
LinkOut - more resources
Full Text Sources